Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer

• Verfasst von: Zörnig, Inka [VerfasserIn]
• Verfasst von: Lahrmann, Bernd [VerfasserIn]
• Verfasst von: Grabe, Niels [VerfasserIn]
• Verfasst von: Jäger, Dirk [VerfasserIn]
• Verfasst von: Halama, Niels [VerfasserIn]
• Titel: Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer
• Titelzusatz: A possible link to treatment resistance
• Verf.angabe: Inka Zoernig, Claudia Ziegelmeier, Bernd Lahrmann, Niels Grabe, Dirk Jäger, Niels Halama
• E-Jahr: 2013
• Jahr: March 5, 2013
• Umfang: 4 S.
• Fussnoten: Gesehen am 02.08.2021
• Titel Quelle: Enthalten in: Oncology reports
• Ort Quelle: Athens : Spandidos Publ., 2001
• Jahr Quelle: 2013
• Band/Heft Quelle: 29(2013), 5, Seite 1697-1700
• ISSN Quelle: 1791-2431
• DOI: doi:10.3892/or.2013.2324
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1765224330

Abstract

ABCG2 is a multidrug cellular transport protein that is associated with resistance to certain treatments in patients, particularly anticancer treatment. The tumor-protective properties of ABCG2 expression are reported to be a feature of a subset of stem cell-like tumor cells. While protection against chemotherapy has been well analyzed, the role of ABCG2 in the treatment with tyrosine kinase inhibitors is only partially understood. Tyrosine kinase inhibitors are currently the main treatment option in irresectable renal cell carcinomas. To investigate possible underlying sequence variations in the ABCG2 gene with relevance to the functional properties of the protein, 36 patient samples were analyzed. Using sequence analysis and single-nucleotide polymorphism databases, sequence variations in the highly conserved domains of the binding pocket of ABCG2 were analyzed. The resulting variations were used for computational protein prediction algorithms to identify conformational alterations. A relevant shift from A to G at position 1376 (resulting in Y→C at 459 aa) was identified and found to be present in 8.3% of the patients. These patients are currently in follow-up after resection, thus, further analysis will reveal whether this mutation has relevance to treatment efficacy.